

Special Issue

Antimicrobial Peptides as New Weapons to Fight Antimicrobial Resistance

Message from the Guest Editor

The emergence of resistance to multiple antimicrobial agents has become a serious public health threat with great social and economic impacts. It should also be highlighted that the discovery, development, manufacture, and marketing of new antibiotics has significantly slowed down in the past 20 years. Thus, effective alternative strategies to conventional antibiotics are urgently needed. Consequently, naturally occurring host defence peptides (HDPs), first called antimicrobial peptides (AMPs), have attracted considerable attention because of their antimicrobial, anti-biofilm, and immunomodulatory properties but, above all, because they generally do not lead to selection of resistant strains, since this would require an almost complete remodeling of the bacterial membrane architecture.

Guest Editor

Dr. Angela Arciello

Department of Chemical Sciences, University of Naples Federico II, Via Cinthia 4, 80126 Naples, Italy

Deadline for manuscript submissions

closed (1 December 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/61293

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)